Aprameya Engineering Limited has secured a working capital facility of Rs 5.84 Crores from Punjab National Bank to support its business credit requirements. The loan agreement was executed on June 24, 2026, under the Emergency Credit Line Guarantee Scheme (ECLGS) 5.0, providing the company with necessary liquidity for its operations.

The facility is a Working Capital Term Loan, fully secured by a comprehensive charge on the company's assets. Security includes manufacturing materials, raw materials, stock in process, semi-finished goods, and bought-out goods. Additionally, the loan is backed by book debts, outstanding decrees, money receivables, government subsidies, claims, bill contracts, and investments. The mortgage of the company's immovable properties further secures the borrowing.

Key Loan Details

The disclosure confirms that Punjab National Bank is not related to the promoter or promoter group of Aprameya Engineering . The transaction does not qualify as a related party transaction and was conducted at arm's length. The agreement contains normal terms standard for such loan facilities.

Aprameya Engineering Limited announced that its 70%-owned subsidiary, Aprameya Medtech Private Limited, has entered into a strategic marketing agreement with Sonoscape Medical India Private Limited. The agreement grants Aprameya Medtech exclusive rights to sell and market SonoScape’s advanced Minimally Invasive Surgery (MIS) portfolio across Southern and Western India. This partnership aims to transform Aprameya from a project-led business into an integrated Healthcare Infrastructure and Medical Equipment platform.

The alliance leverages SonoScape’s technology, which serves clinicians in over 170 countries. SonoScape Medical Corp. is a publicly listed entity that integrates ultrasound, endoscopy, and surgical visualization under one roof, supported by 7 global R&D centres and over 1,035 patents. The collaboration intends to bring high-margin medical equipment sales to complement Aprameya’s existing hospital infrastructure projects.

The product portfolio includes visualization platforms ranging from value-focused full-HD systems to flagship 4K NIR 3D towers. These systems are designed for various hospital segments, from premium tertiary care centres to value-conscious tier-2 and tier-3 hospitals.

Strategic Rationale and Future Plans

The partnership targets a structurally growing market for minimally invasive surgical devices in India, projected to roughly double by 2033. Aprameya Medtech plans to build a dedicated MIS vertical encompassing clinical demonstrations, surgeon training, installation, and after-sales service. Additionally, the companies intend to evaluate manufacturing these systems in India, aligned with the Government of India’s ‘Make in India’ vision. Aprameya Medtech’s upcoming ~45,000 sq. ft. facility, expected operational by the end of CFY 2026–27, may support this localisation effort.